Hellman Jordan Management Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Hellman Jordan Management Company’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,527	Closed	-$329K	–	53
2016 Q3	$329K	Buy	+2,527	New	+$325K	0.33%	43
2015 Q2	–	Sell	-60,329	Closed	-$10.5M	–	56
2015 Q1	$10.5M	Sell	60,329 -7,197	-11%	-$1.3M	1.91%	25
2014 Q4	$12.5M	Buy	67,526 +17,600	+35%	+$3.26M	2.33%	19
2014 Q3	$8.28M	Buy	+49,926	New	+$8.2M	1.57%	32

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Hellman Jordan Management Company's ALXN Position: Q4 2016 in Review

Hellman Jordan Management Company sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 2,527 shares — an estimated $329K sold.

Hellman Jordan Management Company first reported a position in ALXN in Q3 2014 and held it in 4 quarters. The position peaked at $12.5M in Q4 2014. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Hellman Jordan Management Company reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Hellman Jordan Management Company sold 2,527 Alexion Pharmaceuticals shares in Q4 2016, an estimated $329K.
Hellman Jordan Management Company first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Hellman Jordan Management Company's Alexion Pharmaceuticals position peaked at $12.5M in Q4 2014.
549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Hellman Jordan Management Company's 13F filing for Q4 2016, filed 1 Feb 2017.